Name: Frontier Score for "Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial"
Rating: 64
Author: Frontier

What it is

Werner syndrome helicase (WRN) is a synthetic lethal target for microsatellite instability (MSI) cancers. In part 1 of this ongoing first-in-human, phase 1 trial, escalating doses of RO7589831 (VVD-133214), a first-in-class, WRN covalent inhibitor, were evaluated in 88 patients with MSI and/or deficient DNA mismatch repair advanced solid tumors.

Every metric behind this entry is listed, with its source, under Sources and data below.

Filed underGenetic factors in colorectal cancer, PARP inhibition in cancer therapy, DNA Repair Mechanisms

Scored 2026-10-06How scoring works

The Frontier Score, in full

How this entry's score is built, term by term. Open any pillar to see each sub-metric's raw value, how it maps to 0 to 100, and the record that holds it.

The three pillars as one shape: a result strong on every axis fills the triangle.

How the Frontier Score is calculated for this breakthrough
Term	Score	Weight	Points
EvidenceHow established and verifiable the result is.	88	× 0.25	22.0
ImpactHow much the result matters, judged field-relative and by current momentum.	52	× 0.25	12.9
NoveltyHow genuinely new the result is, and how fast-moving.	60	× 0.50	30.2
Weighted pillars			65.1
Frontier recency0 months since publication		× 0.99
IntegrityNot retracted		× 1
Frontier Score			64

Confidence: Early signalEarly signal: little citation history yet, so impact is an estimate and may shift as the work is taken up. Corroborated beyond citations (1 clinical trial).

Every sub-metric, traced to its source

EvidenceHow established and verifiable the result is.88

Evidence sub-metrics
Sub-metric	Raw value	0 to 100	Weight	Points	Source
Peer review & venueWhether the work has cleared peer review, and how selective its venue is. Peer review is necessary but not sufficient: before citations accrue, a fresh result in one of the five general flagships (Nature, Science, Cell, NEJM, the Lancet) is a stronger evidence signal than one in a selective specialist or society journal, which in turn outranks one in a legitimate but very high-volume mega-journal, and any of them outranks a preprint that has not been reviewed at all.Maps to 0 to 100: Peer-reviewed article graded by venue tier: flagship journal (Nature, Science, Cell, NEJM, the Lancet) 100; selective journal (the specialist journals of those families, JAMA, PNAS, Physical Review Letters and X) 90; high-volume mega-journal (Nature Communications, Science Advances) 78. Review 90, book 70, dataset 60, preprint 45, other 55.	Peer-reviewed, selective journal	90	0.30	27.0	OpenAlex type / primary_location / source
CorroborationIndependent corroboration that the result is real and being taken up, read as the BREADTH of agreement rather than the size of the citation pile. Counts how many of the five independent citation indices (OpenAlex, Crossref, Semantic Scholar, OpenCitations, Europe PMC) report the work at all, plus orthogonal, non-citation lines of corroboration: entry into the encyclopedia, registered clinical trials, released datasets or software, public funding on record, and technical-community discussion. Citation MAGNITUDE is deliberately judged under Impact, not here, so Evidence and Impact measure genuinely different things instead of both rewarding the same citation pile twice.Maps to 0 to 100: Starts at 28 and rises with each of the five independent citation indices that agree the work is cited (+9 each) and each orthogonal non-citation corroboration line (+6 each: Wikipedia, clinical trials, open datasets or software, public funding, community discussion). Capped at 100.	4 of 5 citation indices agree, 1 independent non-citation line	70	0.30	21.0	OpenAlex, Crossref, Semantic Scholar, OpenCitations, Europe PMC, DataCite, NIH RePORTER, Wikipedia, Hacker News count of agreeing indices + orthogonal reach
VerifiabilityHow openly the result can be read, reused, and reproduced. Rewards open access, a permissive reuse license (CC-BY/CC0), a green repository copy anyone can archive, openly minable full text, and released datasets or software a reader can actually run. Cross-checked across OpenAlex, Unpaywall, Europe PMC, and DataCite.Maps to 0 to 100: Closed 45; open access 80+; a permissive CC license 100; a repository copy, open full text, or a released dataset/software artifact each raise the floor.	Open access (hybrid), CC-BY	100	0.20	20.0	OpenAlex, Unpaywall, Europe PMC, DataCite is_oa / license / has_repository_copy / open datasets
IntegrityRetraction and post-publication correction status. A retracted result is not evidence of anything and collapses the whole Frontier Score; a correction or expression of concern is a softer flag. Read across OpenAlex and Crossref (both update-to and updated-by notices).Maps to 0 to 100: Clean 100; a correction or expression of concern 75; retracted 0. Flagged if OpenAlex OR Crossref records the notice.	No retraction or concern on record	100	0.20	20.0	OpenAlex, Crossref is_retracted / update-to / updated-by

ImpactHow much the result matters, judged field-relative and by current momentum.52

Impact sub-metrics
Sub-metric	Raw value	0 to 100	Weight	Points	Source
Field-normalized impactImpact relative to the world average for the same field, year, and type, so a small field and a large field are judged fairly. Triangulates three independent field-normalized measures: OpenAlex's Field-Weighted Citation Impact, its citation percentile within the exact field-and-year cohort, and the NIH iCite Relative Citation Ratio. 1.0x is average; the percentile is the share of same-field, same-year work it out-cites.Maps to 0 to 100: Each ratio (1.0 = field average) maps 1.0 to 50, 3.0 to 75, 9.0 to 90; the field+year percentile maps directly (top 1% -> ~99). The available measures are averaged. Falls back to a saturating citation count when none is available yet.	4.9x FWCI, top 4% of field-year vs field	90	0.45	40.3	OpenAlex, NIH iCite fwci / citation_normalized_percentile / relative_citation_ratio
Influential citationsCitations that genuinely build on the work rather than mention it in passing (Semantic Scholar's influential-citation measure). A sharper signal of real impact than a raw count.Maps to 0 to 100: Saturating: 15 influential citations maps to 50. Falls back to a fraction of consensus citations when unavailable.	Not yet available	n/a	redistributed	0.0	Semantic Scholar influentialCitationCount
Citation velocityCitations received in the trailing twelve months, judged as a rate rather than a lifetime total. Momentum is what a frontier index cares about: a result being taken up fast right now is landing, whether its lifetime pile is large or still small. Where an expected field citation rate is known, the momentum is also read relative to it, so a fast-moving result in a quiet field is not overlooked.Maps to 0 to 100: Saturating: 30 citations in the last twelve months maps to 50. When NIH iCite provides the field's expected rate, this is blended evenly with the ratio of observed to expected momentum.	1 in last 12 months	3	0.35	1.1	OpenAlex, NIH iCite counts_by_year / field_citation_rate

NoveltyHow genuinely new the result is, and how fast-moving.60

Novelty sub-metrics
Sub-metric	Raw value	0 to 100	Weight	Points	Source
Conceptual noveltyHow genuinely new the contribution is, measured at publication from the work's OWN content, not its date: how atypical its combination of research areas is versus all prior work, and whether it builds on a broad, deep base rather than only the newest papers in a fast-moving area. This is what separates a real advance from a recent-but-commodity result, and it needs no forward citations, so it is stable for brand-new work. An honestly noisy proxy (even state-of-the-art novelty measures agree only moderately with expert judgment), so it carries bounded weight and never drives the ranking alone.Maps to 0 to 100: Blends two publication-time signals, each 0-100: an atypical-combination score (how unusual the pairing of the work's research topics is versus the prior literature, by pointwise mutual information) and a foundational-reach score (median age and depth of the work's references). The stronger signal weighs 0.62, the weaker 0.38. When neither is measurable (a work too thin in topics or references), the pillar renormalizes over its recency signals instead.	Genetic factors in colorectal cancer x PARP inhibition in cancer therapy (1,229 prior works made this pairing); builds on refs a median 3.0y deep	30	0.45	13.7	OpenAlex topics + referenced_works (publication-time)
RecencyHow recently the work appeared. The frontier is now, so newer scores higher.Maps to 0 to 100: Exponential decay with a 12-month half-life from the publication date.	This month	99	0.30	29.6	OpenAlex publication_date
Attention accelerationWhether attention is rising: citations in the latest full year versus the year before. Accelerating interest signals an active, opening frontier.Maps to 0 to 100: Latest/prior-year ratio: 1x maps to 50, 2x to 75, 4x to 100. Unknown is neutral.	Not enough history	50	0.10	5.0	OpenAlex counts_by_year
Edge of reviewPreprints and brand-new work sit ahead of the peer-review process. That earns novelty here (while it is discounted under Evidence), because it is where the frontier forms first.Maps to 0 to 100: Preprint 95, article <6 months 80, article <18 months 65, else 45.	Peer-reviewed record	80	0.15	12.0	OpenAlex type / publication_date

ProvenanceAll sources

Sources and data

Every number behind this entry, grouped by the source that holds it: up to five citation indices cross-checked, field-normalized impact, then real-world reach (Wikipedia, community discussion, clinical trials, released data and public funding) where it exists. Each value links to its record.

OpenAlex

Primary record

Total citations: 1
Field-weighted citation impact: 4.9x field average
Citation percentile: Top 4% of its field-year
Citations, recent 12 months: 1
Publication date: 2026-09-29
Access: Open access (hybrid)

Crossref

Citations: 0
Works it builds on: 47

OpenCitations

Citations: 0

Europe PMC

Citations: 0

Unpaywall

Reuse license: CC-BY

ClinicalTrials.gov

Registered clinical trials: 1 (to phase 1)

OpenAlex record Read it in Nature Medicine

For the authors

Show this score where your work lives

A badge for your lab page, your CV or the paper's code repository. It links readers to this entry, and it always carries the entry's current score.

Live preview

<a href="https://frontierresearch.co/breakthroughs/werner-helicase-inhibitor-for-advanced-microsatellite-in-w7214750205?utm_source=badge&amp;utm_medium=badge&amp;utm_campaign=author-kit"><img src="https://frontierresearch.co/api/badge/W7214750205.svg" alt="Frontier Score for this paper" height="20"></a>

For a lab or personal website, a CV page, or anywhere that takes HTML.

The number is live. The badge is drawn from the same signals as this page, so it never shows a score the entry does not. Every entry is re-checked weekly against the same public sources, and a result's standing eases as it ages, so the active edge of the field stays on top. How scoring works

Something wrong or out of date? Write to hello@frontierresearch.co and the entry will be corrected.

Biomedicine & HealthThe whole field

Biomedicine & Health · Notable

MemBrain v2: an end-to-end tool for the analysis of membranes in cryo-electron tomography

E 88I 90N 72Sep 8, 2026

Biomedicine & Health · Notable

Comparative analysis of mitochondrial proteomes across the tree of life

E 92I 50N 77Oct 1, 2026

Biomedicine & Health · Notable

Cohesin prevents local mixing of condensed euchromatic domains in living human cells

E 91I 54N 81Sep 1, 2026

Back to the Frontier Index, or browse every breakthrough by date.

What it is

The Frontier Score, in full

Sources and data

OpenAlex

Crossref

OpenCitations

Europe PMC

Unpaywall

ClinicalTrials.gov

Show this score where your work lives

Related on the frontier

MemBrain v2: an end-to-end tool for the analysis of membranes in cryo-electron tomography

Comparative analysis of mitochondrial proteomes across the tree of life

Cohesin prevents local mixing of condensed euchromatic domains in living human cells

The week's Biomedicine & Health, scored.